Fierce Biotech August 21, 2024
Cancer diagnostics startup PreciseDx picked up $20.7 million in series B funding as it ramps up commercialization efforts for its AI-based breast cancer risk assessment.
The company, a Fierce Medtech Fierce 15 of 2022 honoree, developed oncology diagnostics leveraging artificial intelligence for new, morphology-driven disease analysis.
The round was led by Eventide Asset Management and was also backed by Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors. PreciseDx has raised $31.5 million in total funding to date.
The funding comes on the heels of a number of key achievements by PreciseDx, including completion of two successful validation studies (analytical and clinical); receipt of CLIA Standard approval and CLEP NYSDOH review on the PreciseBreast assessment; a Cost Impact...
Today's Sponsors
Today's Sponsor